CME Group reported record average daily trading volumes of 41.1 million contracts in March, a 33% year-over-year increase, with the first quarter averaging 36.2 million contracts (+22% YoY). This surge in activity spanned all major segments, including interest rates and commodities, indicating robust demand for risk-hedging instruments. UBS has raised its Q1 2026 EPS forecast to $3.38, driven by these rising volumes, although it maintains a Neutral rating with a $310 price target, suggesting limited upside due to pricing pressures and potential peak activity.
Despite these challenges, CME’s stock has shown resilience, up approximately 14% year-to-date, outperforming the S&P 500, which has declined over 10% in the same period. Raymond James holds an Outperform rating, citing competitive weaknesses in the FMX platform as a supportive factor for CME. Investors should consider CME as a defensive play in a volatile market, while being mindful of potential short-term resistance around the $315–320 range.
Source: xtb.com